Pacemakers refer to small devices that are placed in the chest to help control the heartbeat. It is being used to prevent the heart from beating too slowly. The pacemaker is used to treat fainting spells, congestive heart failure, and hypertrophic cardiomyopathy. The main types of pacemakers are MRI compatible pacemakers and conventional pacemakers. The MRI-compatible pacemakers are the devices that pose no known hazards in a specified MRI environment under specific devices and MRI scanner conditions. The various technologies include single-chamber pacemaker, dual-chamber pacemaker, and biventricular or CRT pacemakers, which have different implantability, such as implantable pacemaker, and external pacemaker. The numerous applications include congestive heart failure, arrhythmias, bradycardia, and tachycardia that are used by various end users, including hospitals, cardiac care centres, ambulatory surgical centers, and others. The pacemakers market research report is one of a series of new reports from The Business Research Company that provides pacemaker market statistics, including pacemaker industry global market size, regional shares, competitors with a pacemaker market share, detailed pacemaker market segments, market trends and opportunities, and any further data you may need to thrive in the pacemakers industry. This pacemaker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pacemakers market size grew from $4.89 billion in 2022 to $5.17 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pacemakers market size is expected to grow to $6.16 billion in 2027 at a CAGR of 4.5%. The increasing prevalence of cardiovascular diseases is contributing to the growth of the pacemaker market going forward. The increasing prevalence of cardiovascular diseases is due to risk factors such as unhealthy diets, tobacco use, and harmful use of alcohol. Pacemakers include flexible and insulated wires that are helpful in controlling cardiovascular diseases by controlling irregular heart rhythms. For instance, in 2021, according to the World Health Organization, a Switzerland-based government agency, India would account for one-fifth of the total deaths occurring from stroke and ischemic heart disease, mainly in younger adults. Additionally, according to the Center for Disease Control and prevention, an American national public health agency, approximately 697,000 people in the US died from heart disease in 2020 which converted to almost 1 in 5 deaths. Therefore, the increasing prevalence of cardiovascular diseases will drive the growth of the pacemaker market. Technological advancements have emerged as a key trend gaining popularity in the pacemaker market. Major companies operating in the pacemaker market are focused on developing new technological solutions to strengthen their position. For instance, in October 2020, Medtronic plc, an Ireland-based medical technology company, launched Azure pacemakers based on BlueSync technology in India. Azure pacemakers are India's first pacemakers that communicate directly with patients' smartphones and tablets. Azure is designed to accurately detect and reduce the likelihood of atrial fibrillation. It will offer improved longevity (up to 13.7 years), so patients could potentially need fewer device replacements and will allow patients to have MRI scans in either 1.5 or 3 Tesla (T) machines. This will enable automatic, secure wireless communication through Bluetooth Low Energy and remote monitoring through the Medtronic CareLink Network, providing more timely alerts of clinically relevant patient events that can be reviewed by a clinician at any time. In January 2021, Boston Scientific, a US-based manufacturer of medical devices, acquired Preventice Solutions, Inc. for a deal amount of $925 million. The acquisition is expected to give Boston Scientific a foothold in the fast-growing ambulatory electrocardiography market, which will complement the company's recent entry into the implantable cardiac monitor market and serve as a key component of its category leadership strategy in cardiac diagnostics and services. Preventice Solutions, Inc. is a US-based medical device company that provides mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors to cardiac event monitors and mobile cardiac telemetry. Major players in the pacemakers market are Boston Scientific Corporation, ZOLL Medical Corporation, Medtronic plc, Biotronik, MicroPort Scientific Corporation, Cook Medical, MEDICO SpA, Shree Pacetronix Ltd., Oscor Inc., Osypka Medical GmbH, Abbott Laboratories, LivaNova PLC, Lepu Medical Technology (Beijing) Co. Ltd., Cordis Inc., St. Jude Medical Inc., and Vitatron. North America was the largest region in the pacemaker market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pacemaker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pacemaker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The pacemakers market consists of sales of leadless pacemakers and transvenous peacemakers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pacemakers market is segmented - 1) By Type: MRI Compatible Pacemaker, Conventional Pacemaker 2) By Technology: Single-Chamber Pacemaker, Dual-Chamber Pacemaker, Biventricular or CRT Pacemaker 3) By Implantability: Implantable Pacemaker, External Pacemaker 4) By Application: Congestive Heart Failure, Arrhythmias, Bradycardia, Tachycardia 5) By End-User: Hospitals, Cardiac Care Centres, Ambulatory Surgical Centres, Other End Users

Cardiac assist devices and equipment are electromechanical devices that assist in pumping blood from the heart to the rest of the body. These devices are used either to partially or completely replace the function of a failing heart. The main types of cardiac assist devices and equipment are ventricular assist devices, intra-aortic balloon pumps, and the total artificial heart. Ventricular assist devices are electromechanical devices used to help with cardiac circulation. The various types of modalities are transcutaneous and implantable. These are used in hospital pharmacies, ambulatory surgical centres, and emergency services. The cardiac assist devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiac assist devices and equipment market statistics, including cardiac assist devices and equipment industry global market size, regional shares, competitors with a cardiac assist devices and equipment market share, detailed cardiac assist devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac assist devices and equipment industry. This cardiac assist devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiac assist devices and equipment market size will grow from $2.15 billion in 2022 to $2.41 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac assist devices and equipment market size is expected to grow to $3.51 billion in 2027 at a CAGR of 9.9%. A rise in the prevalence of cardiovascular diseases increases the demand for cardiac assist devices and equipment in developed and developing economies. The increasing need for diagnosis, monitoring, early-stage treatment, and prevention of these life-threatening diseases, increase the demand for cardiac assist devices. According to the American Heart Association, by 2035, 45.1% of the US population is projected to have some form of CVD. Total costs of CVD are expected to reach $1.1 trillion in 2035, with direct medical costs projected to reach $748.7 billion and indirect costs estimated to reach $368 billion. According to the Centers for Disease Control and Prevention, anout 697,000 people died from heart diseases in 2020 which was almost 1 in every 5 deaths. Risks associated with the implantation of cardiac assist devices into the human body acts as a major restraint for the growth of this market. Risks associated with device implantation include respiratory failure, blood clot formation, occurrences of stroke, and the risk of device failure leading to a heart attack are some major reasons due to which people are hesitant to adopt cardiac assist devices, thus the demand from end-users of cardiac assist devices remains restrained, therefore limiting the growth prospects of the market. The infection rate of cardiac implantable electronic devices is 1.7% initially after implantation, whereas after 2years the infection rate is 9.5%, increasing the risk factor. The rising number of device replacements results in complex procedures, considerable risks with an increase in infection rates. Device miniaturization is becoming popular in the cardiac assist devices and equipment market. The concept of minimizing the size of the cardiac assist devices enhances device implantation, provides potentially shorter hospital stay through the use of less invasive surgery such as 'Thoracotomy'. Cardiac assist device miniaturization acts as a replacement to heart transplantation as destination therapy, due to lack of heart donors. For instance, Heartware Ltd. is increasingly investing in the Heartware's device miniaturization program, aiming to reduce the weight, size, and energy consumption of the device. Furthermore, the United Kingdom National Health Service has invested in a Bridge to Transplant program (BTT) where the performance of two minimally invasive cardiac assist devices was compared, out of which the best one was found based on better clinical outcome and more cost-effectiveness due to its miniaturized design. In June 2021, Medtronic PLC., an Irish medical device company, stopped the sale and distribution of the HeartWare Ventricular Assist Devices system due to the risk of mortality and neurological adverse events due to the use of the device and malfunctioning in the starting of the device. Major players in the cardiac assist devices and equipment market are Abbot Laboratories, Berlin Heart GmbH, Abiomed Inc., Bivacor Pvt Ltd., Calon Cardio - Technology Ltd., Cardiobridge GmbH, Balton Sp. Z O.O, Cardiac Assist Inc., Braile Biomedica Ltd., and Circulate Inc. North America was the largest region in global cardiac assist devices and equipment market in 2022. Western Europe was the second-largest region in cardiac assist devices and equipment market. The regions covered in global cardiac assist devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiac assist devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The cardiac assist devices and equipment market consist of sales of ventricular assist devices (LVAD), intra-aortic balloon pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiac assist devices and equipment market is segmented - 1) By Type: Ventricular Assist Devices (LVAD), Intra-Aotic Baloon Pumps, Total Artificial Heart 2) By Application: Hospital Pharmacies, Ambulatory Surgical Centres, Emergency Services 3) By Modality: Transcutaneous, Implantable

Cardiac rhythm management (CRM) devices and equipment are used to manage the heart rate or rhythm by generating electrical impulses or shocks in order to get the heart back to its normal functions. CRM devices are used to treat and manage arrhythmia-related diseases such as cardiac arrests, heart failure, or cardiac arrhythmias. The main products of cardiac rhythm management devices and equipment are pacemakers, defibrillators, and cardiac resynchronization therapy (CRT). A pacemaker is a small device that's placed in the chest to control the heartbeat. It's used to prevent the heart from beating too slowly. The defibrillators are implantable cardioverter defibrillators and external defibrillators. Cardiac resynchronization therapy (CRT) includes CRT-defibrillators (CRT-D), CRT-pacemakers (CRT-P). There are implantable pacemakers and external pacemakers. The applications involved are bradycardia, tachycardia, heart failure, and others that are used by various end-users such as hospitals, ambulatory surgical centres, and physician’s clinics. The cardiac rhythm management (CRM) devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiac rhythm management (CRM) devices and equipment market statistics, including cardiac rhythm management (CRM) devices and equipment industry global market size, regional shares, competitors with a cardiac rhythm management (CRM) devices and equipment market share, detailed cardiac rhythm management (CRM) devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac rhythm management (CRM) devices and equipment industry. This cardiac rhythm management (CRM) devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiac rhythm management (CRM) devices and equipment market size will grow from $15.13 billion in 2022 to $16.19 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac rhythm management (CRM) devices and equipment market size is expected to grow to $20.05 billion in 2027 at a CAGR of 5.5%. The rising incidences of cardiovascular diseases such as cardiac arrhythmia, ischemic heart disease, and hypertension is driving the CRM devices market. Sedentary lifestyles and medical conditions such as high cholesterol, high blood pressure, obesity, and diabetes are major causes of cardiovascular diseases. According to the World Health Organization, cardiovascular diseases account for about 31% of all global deaths. Most of these deaths occur due to heart attacks and strokes. As more people suffer from cardiovascular diseases, the demand for cardiac rhythm management and devices is expected to increase. The risks associated with cardiac rhythm management devices and equipment market is acting as a restraint on the market. CRM devices may pose potential risks such as post-implant infections and contraindications in patients undergoing any type of radiation therapy or diagnosis. Implantable CRM devices contain complementary metal-oxide-semiconductor (CMOS) which may get damaged due to therapeutic doses of radiation. Also, as the implants are highly sensitive devices, any dysfunction may have life-threatening consequences for the patients. The considerable number of risks involved in using CRM devices are affecting the growth of the market. Technologies such as subcutaneous implantable cardioverter-defibrillator (S-ICD) and leadless cardiac pacemakers (LCP) are being developed to overcome complications with transvenous lead and other CRM devices. The novel modular cardiac rhythm management (mCRM) system allows for the coordination of leadless pacing and defibrillator therapy delivery by providing wireless intra-body communication between devices. This communication is possible by a combination of anti-tachycardia pacing-enabled LCP and S ICD. For instance, Medtronic developed the leadless pacemaker Micra which can be placed in the heart through veins and is self-contained within the heart. Manufacturers of cardiac rhythm management devices and equipment are governed by various regulatory bodies such as the FDA in the USA. The United States Food and Drug Administration recalls any product with safety issues or defects that can endanger the consumer. The FDA recalled the Platinium implantable cardiac defibrillator and resynchronization therapy defibrillator due to issues with hardware configuration and functioning. The company had to discard all non-implanted Platinium devices and follow up with all patients implanted with these devices. Major players in the cardiac rhythm management (CRM) devices and equipment market are Abbott, Medtronic, Biotronik, Cardiac Science Corporation, Schiller AG, Hill-Rom Holdings Inc., GE Healthcare, Integer, Biotelemetry, and Neovasc. North America was the largest region in the global cardiac rhythm management (CRM) devices and equipment market in 2022. Western Europe was the second-largest region in the cardiac rhythm management (CRM) devices and equipment market. The regions covered in the global cardiac rhythm management (CRM) devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiac rhythm management (CRM) devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The cardiac rhythm management (CRM) devices and equipment market consist of sales of Pacemakers, (implantable pacemakers, external pacemakers), defibrillators (implantable cardioverter defibrillators, external defibrillators), and cardiac resynchronization therapy (CRT-defibrillators, CRT-pacemakers) that are used for rhythm management. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiac rhythm management (CRM) devices and equipment market is segmented - 1) By Product: Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) 2) By End User: Hospitals, Ambulatory surgical centers, Physicians Clinics 3) By Application: Bradycardia, Tachycardia, Heart Failure, Other Applications 4) By Pacemakers: Implantable Pacemakers, External Pacemakers 5) By Defibrillators: Implantable Cardioverter Defibrillators, External Defibrillator 6) By Cardiac Resynchronization Therapy (CRT): CRT-Defibrillators (CRT-D), CRT-Pacemakers (CRT-P)

Cardiovascular surgery devices and equipment are used in cardiac surgery and other cardiovascular procedures performed to repair structural defects of the cardiovascular system and damaged or blocked valves and vessels. The main product types in the cardiovascular surgery devices and equipment are beating heart surgery systems, cardiopulmonary bypass equipment, cardiac ablation devices, and perfusion disposables. Cardiopulmonary bypass equipment is used in open-heart surgeries and is operated by perfectionists. The various applications are congenital heart defects, cardiac arrhythmia, coronary heart disease, congestive heart failure, and other applications. These are used in home and ambulatory care, hospitals, diagnostic laboratories, and research laboratories. The cardiovascular surgery devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiovascular surgery devices and equipment market statistics, including cardiovascular surgery devices and equipment industry global market size, regional shares, competitors with a cardiovascular surgery devices and equipment market share, detailed cardiovascular surgery devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular surgery devices and equipment industry. This cardiovascular surgery devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular surgery devices and equipment market size will grow from $1.68 billion in 2022 to $1.75 billion in 2023 at a compound annual growth rate (CAGR) of 3.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular surgery devices and equipment market size is expected to grow to $1.91 billion in 2027 at a CAGR of 2.2%. The rising geriatric population along with the rising deaths related to cardiovascular disorders is driving the cardiovascular surgical devices market. According to American Heart Association (AHA), in the US, approximately 43.7 million aged above 60 suffered from cardiovascular disorders. It is also reported by AHA that death related to cardiac diseases amount to 17.3 million per year and is expected to rise to more than 23.6 million by 2030, worldwide. Due to these factors, a higher number of surgeries are being performed, thereby driving the market. The cardiovascular surgical devices market may be restrained due to stringent and longer approval processes by the regulatory authorities. According to a researcher from Harvard Business School, innovative first-mover products such as implantable defibrillators or transcatheter heart valves are delayed for approvals by FDA, thereby adding to the development cost to the manufacturer. For new cardiovascular devices (first-entrants), the innovator spends 7.2 months longer than the first follow-on innovator. For example, Edwards Lifesciences trans-catheter heart valve was approved in Europe 4 years before it was approved in the USA. The study also estimated the financial loss associated with the delay in getting the approval. The delay may cost firms an average of $6.7 million to the already existing $94 million average prices to introduce a new medical device to market, thereby hampering companies’ pursuit of innovations. Companies in the cardiovascular surgery devices and equipment market are investing in second-generation bioresorbable stents and as well rectifying the glitches which occurred in the earlier version of bioresorbable stents. This advancing segment is poised to garner $247 million by 2025. Due to the all-new device features such as thinner strut thicknesses, faster resorption times, and better radial force, these are expected to grow at a higher growth rate. A higher elective procedure volume due to the less-invasive nature of PCIs, when compared to coronary artery bypass grafting, is expected to drive bioresorbable stents adoption. For instance, Amaranth Medical has developed three medical devices with thinner strut thickness, the latest bearing a magnitude of 100 microns. The U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) made public, its priority list for medical device guidance documents. This would allow the companies in promoting innovation and as well save them from the stringent consequences of non-approval of any product. Thus, a clearer and transparent approval method would drive the cardiovascular surgical devices market in the future. Major players in the cardiovascular surgery devices and equipment market are Abbott Laboratories, Boston Scientific Corporation, Cook Medical, C.R.Bard, Abiomed, St.Jude medical, Angiodynamics Inc., Transmedics, Terumo cardiovascular systems corporation, and Edwards Life Science Corporation. North America was the largest region in the global cardiovascular surgery devices and equipment market in 2022. Western Europe was the second-largest region in the global cardiovascular surgery devices and equipment market. The regions covered in the cardiovascular surgery devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular surgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The cardiovascular surgery devices and equipment market consist of sales of perfusion disposables, beating heart surgery systems, cardiopulmonary bypass equipment, and cardiac ablation devices that are used for cardiovascular surgeries. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular surgery devices and equipment market is segmented - 1) By Product Type: Beating heart surgery systems, Cardiopulmonary Bypass Equipment, Cardiac Ablation Devices, Perfusion Disposables 2) By End User: Home and Ambulatory care, Hospitals, Diagnostic laboratories, Research laboratories 3) By Application: Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, Other Applications

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The main types of cardiovascular drugs market are anti-hypertensive drugs, hypolipidemics, anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs). Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cardiovascular drugs market is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs market manufacturers. NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. Major companies in the cardiovascular drugs market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson. North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiovascular drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global cardiovascular drugs market is segmented - 1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

Cardiac valves refer to artificial valves used to keep the flow of blood in one direction from the heart to the rest of the body parts. A cardiac valve is an implantable device used to replace a damaged body valve that has stopped working due to various diseases. The primary function of the cardiac valve is to keep blood flowing in the proper direction through the heart and from the heart into the major blood vessels connected to it. The main types of cardiac valves are tissue, transcatheter, mechanical, and other heart valves. Tissue heart valves refer to heart valves used in open heart or minimally invasive surgery to prevent blood clots inside the vessels. Animal tissue that is robust and flexible is used to make tissue valves from the valves of animal donors. These valves are used in cardiac valve repair and cardiac valve replacement. The aortic valve, mitral valve, and other positions where the cardiac valve is repaired or replaced in the heart. Hospitals and clinics, specialty centers, cardiac research institutes, and others are the end users of cardiac valves. The cardiac valve market research report is one of a series of new reports from The Business Research Company that provides cardiac valve market statistics, including cardiac valve industry global market size, regional shares, competitors with a cardiac valve market share, detailed cardiac valve market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac valve industry. This cardiac valve market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiac valve market size grew from $8.35 billion in 2022 to $9.51 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac valve market size is expected to grow to $15.39 billion in 2027 at a CAGR of 12.8%. The rising incidence of cardiovascular diseases is expected to propel the growth of the cardiac valve market. The prevalence of cardiovascular disease has gradually increased due to smoking, obesity, a lack of physical activity, and other factors that strain the cardiovascular system. The most common cause of coronary artery disease is arteries' build-up of fatty plaques. These gradual increases in heart-related diseases raised the demand for the cardiac valve to treat heart valve problems. According to the Center for Disease Control and prevention, an American national public health agency, approximately 697,000 people in the US died from heart disease in 2020, which converted to almost 1 in 5 deaths. Therefore, the rising incidence of cardiovascular diseases will drive the cardiac valve market. Technological advancements in cardiac valves are a key trend gaining popularity in the cardiac valve market. With advancements in technology, there are less invasive treatment options for heart diseases. Major companies operating in the cardiac valve market are concentrating on technologies such as neochordae implantation, annuloplasty ring, and robotic surgery to strengthen their market position. These innovative technologies help to protect patients from life-threatening conditions such as heart stroke and cardiac arrest. For instance, in July 2020, LivaNova PLC, a UK- based cardiac surgery and neuromodulation device manufacturing company, launched Perceval Plus sutureless surgical aortic heart valve based on sutureless surgical technology. This sutureless technology offers minimally invasive heart surgery with anti-calcification treatment with long durability. Furthermore, in September 2020, Boston Scientific Corporation, a US-based medical technology company, launched transcatheter aortic valve implantation (TAVI) technology. This technology is used for aortic stenosis treatment by lowering mortality, complications, and surgical cost for the treatment of heart diseases. In January 2022, Venus Medtech, the China-based structural heart disease treatment company, acquired Cardiovalve Ltd. for an undisclosed amount. With this acquisition, Venus Medtech will continue progressing clinical research in Europe and the United States while accelerating clinical development and commercialization in China. This acquisition would allow Venus Medtech to become China's most comprehensive platform for treating mitral and tricuspid regurgitation. Cardiovalve Ltd. is an Israel-based medical device company developing a transfemoral mitral valve replacement system. Major players in the cardiac valve market are LivaNova PLC, Abbott Laboratories, Colibri Heart Valve LLC, TTK HealthCare Limited, Artivion Inc., JenaValve Technology Inc., Edwards Lifesciences Corporation, Lepu Medical Technology Co., Ltd., Braile Biomédica, Foldax Inc., Sorin SpA, Neovasc Inc., The RUA Life Sciences group, Translumina Therapeutics Private Limited, and On-X Life Technologies. North America was the largest region in the cardiac valve market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac valve market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cardiac valve market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The cardiac valve market consists of sales of tricuspid valves and pulmonary valves. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiac valve market is segmented - 1) By Type: Tissue Heart Valves, Transcatheter Heart Valves, Mechanical Heart Valves, Other Types 2) By Position: Aortic Valve, Mitral Valve, Other Positions 3) By Treatment: Cardiac Valve Repair, Cardiac Valve Replacement 4) By End-Users: Hospital And Clinics, Specialty Centers, Cardiac Research Institute, Other End Users

Cardiovascular devices are used to monitor and control the irregular heartbeats and heart rhythm disorders. The main types in the cardiovascular devices market are cardiovascular surgery devices and equipment, cardiac rhythm management (CRM) devices and equipment, interventional cardiology devices and equipment, defibrillator devices and equipment, peripheral vascular devices and equipment, prosthetic heart valve devices and equipment, electrophysiology devices and equipment, and cardiac assist devices and equipment. Defibrillators are devices that restore the normal heartbeat by sending an electric pulse or shock to the heart. They are used to prevent or correct an arrhythmia, a heartbeat that is uneven or slow or fast. The type of expenditure is public, or private. The products used are instruments/equipment, and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The cardiovascular devices market research report is one of a series of new reports from The Business Research Company that provides cardiovascular devices market statistics, including cardiovascular devices industry global market size, regional shares, competitors with a cardiovascular devices market share, detailed cardiovascular devices market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular devices industry. This cardiovascular devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cardiovascular devices market grew from $59.55 billion in 2022 to $64.39 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular devices market is expected to grow to $83.35 billion in 2027 at a CAGR of 6.7%. Leadless pacemakers are being used for certain medical conditions such as slow heart rate (bradycardia), as they provide a less-invasive alternative to conventional pacemakers. A leadless pacemaker is a self-contained device that is inserted in the right ventricle of the heart without incisional access, leads, or a surgical pocket. Furthermore, the medical procedure for a leadless pacemaker can be performed in under 30 minutes, with few postprocedural restrictions. These devices are gaining popularity as they eliminate complications related to lead placement which includes cardiac perforation, pneumothorax, and lead dislodgement. Major companies manufacturing leadless pacemakers are Medtronic and Abbott. Major companies in the cardiovascular devices market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc., and Becton Dickinson. North America was the largest region in the global cardiovascular devices market in 2022. Western Europe was the second largest region in the global cardiovascular devices market. Africa. was the smallest region in the global cardiovascular devices market. The regions covered in the cardiovascular devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cardiovascular devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The cardiovascular devices market consists of sales of biventricular devices, and implantable cardiac loop recorders that are used for monitoring and treatment of cardiovascular disorders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular devices market is segmented - 1) By Type: Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Cardiovascular monitoring and diagnostic devices and equipment are used for the diagnosis, monitoring, and treatment of cardiovascular diseases. The main product types of cardiovascular monitoring and diagnostic devices and equipment are cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and Holter monitoring systems. ECG monitoring equipment is an electronic device that is used to record the electrical activity of the heart. The various types involved are heart disease and coronary heart disease. The various end-users involved are hospitals/physician clinics (continuous glucose monitors), home/emergency, and research and development (clinical trials, universities, CRO). The cardiovascular monitoring and diagnostic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiovascular monitoring and diagnostic devices and equipment market statistics, including cardiovascular monitoring and diagnostic devices and equipment industry global market size, regional shares, competitors with a cardiovascular monitoring and diagnostic devices and equipment market share, detailed cardiovascular monitoring and diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular monitoring and diagnostic devices and equipment industry. This cardiovascular monitoring and diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular monitoring and diagnostic devices and equipment market size will grow from $3.12 billion in 2022 to $3.36 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular monitoring and diagnostic devices and equipment market size is expected to grow to $4.31 billion in 2027 at a CAGR of 6.4%. The cardiovascular monitoring and diagnostic devices and equipment market is being driven by an increasing number of people suffering from obesity and diabetes. Risk factors including high blood pressure and high cholesterol are associated with obesity and diabetes leads to cardiovascular diseases. For instance, as per a study conducted by the American Heart Association (AMA), by 2030, 22.2 million CVD is expected to grow. According to another study conducted by AMA in the U.S., 26 million people have been diagnosed with diabetes, and above 9 million further, have the condition but it hasn't yet been diagnosed. The cardiovascular monitoring and diagnostic devices and equipment market is being restrained by the FDA's regulatory control over these devices based on the risks associated with this equipment. Cardiovascular monitoring and diagnostic devices fall into the class II category as per the FDA, which includes devices with moderate to high risk associated with usage. The Class II devices are specially controlled with performance standards which provide the manufacturers with performance specifications, postmarket surveillance which monitors the safety of the device after being released in the market, and also other standards like patient registries and special labeling requirements. For instance, Angel medical systems’ implantable cardiac monitor was unanimously rejected by a panel of FDA experts due to unmet performance specifications. ICMs continuously monitor the electrocardiogram (ECG) of the patient to conduct a real-time examination of the heart rhythm, for up to 36 months. ICMs are mostly used in the analysis of transitory symptoms which have an arrhythmic origin, such as unexplained palpitations. For example, in July 2020, Medtronic received U.S. Food and Drug Administration (FDA) clearance and European CE label approval for its Linq II insertable cardiac monitor (ICM) by remote programming, allowing clinicians to optimize device settings without the requirement for patients to return to the hospital. The launch of new products is a key trend gaining popularity in the cardiovascular monitoring and diagnostic devices and equipment market. Companies in the market are focusing on the launch of new products to improve their product portfolio and strengthen their market position. For example, in August 2022, SmartCardia SA, a medical equipment manufacturer in Switzerland, launched 7L patch, its 7-lead cardiac monitoring patch in India. This patch monitor combines medical wearable technology with artificial intelligence (AI) to provide predictive and personalized patient insights through remote monitoring. The 7L patch is tracked by SmartCardia’s AI platform is interpreted by cardiologists and certified cardiac technicians and performs real-time detection of important arrhythmia events at cardiologist level accuracy. The US FDA has classified cardiovascular monitoring and diagnostic devices into the Class II category, as they have a moderate to high risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, postmarket surveillance, and labeling requirements associated with device usage. For instance, the labeling should consist of contraindications, adverse reactions, precautions, warnings, and other instructions before the device is released into the market. Major players in the cardiovascular monitoring and diagnostic devices and equipment market are Medtronic PLC., Boston Scientific Corporation, GE Healthcare, Johnson & Johnson, Philips Healthcare, Siemens Healthcare, St. Jude MedicalInc., Nihon Kohden Corporation, FUKUDA DENSHI Co. Ltd., and Sorin Group. North America was the largest region in global cardiovascular monitoring and diagnostic devices and equipment market in 2022. Western Europe was the second-largest region incardiovascular monitoring and diagnostic devices and equipment market. The regions covered in global cardiovascular monitoring and diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular monitoring and diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The cardiovascular monitoring and diagnostic devices and equipment market consist of sales of cardiopulmonary stress testing systems, ECG data management systems, ECG monitoring equipment, ECG stress testing systems, event monitoring systems, and holter monitoring systems that are used for diagnosis and treatment of cardio diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular monitoring and diagnostic devices and equipment market is segmented - 1) By Product Type: Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testing Systems, Event Monitoring Systems, Holter Monitoring Systems 2) By End-Use: Hospitals/Physician Clinic (Continuous Glucose Monitors), Home/Emergency, Research and Development (Clinical Trials, Universities, CRO) 3) By Type: Heart Disease, Coronary Heart Disease